Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

PHASE4CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions
Chronic Kidney DiseasesHyperkalemia
Interventions
DRUG

Patiromer

Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.

DIETARY_SUPPLEMENT

Research Diet Menu

During the study, participants will be asked to consume only the foods provided in the research diet

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03183778 - Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. | Biotech Hunter | Biotech Hunter